NeuroBo Pharmaceuticals with ticker code (NRBO) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 30 and 20 calculating the mean target price we have 25. With the stocks previous close at 6.13 this is indicating there is a potential upside of 307.8%. There is a 50 day moving average of 5.5 and the 200 day moving average is 6.64. The company has a market capitalisation of $102m. Visit the company website at: http://www.neurobopharma.com
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals was incorporated in 2017 and is headquartered in Boston, Massachusetts.